GeneDx shares plunge 49% after missing earnings and cutting 2026 guidance, triggering securities fraud lawsuit.

GeneDx Holdings Corp. shares fell over 49% after the company reported weaker-than-expected Q1 results and lowered its 2026 revenue guidance from $540-555 million to $475-490 million. The company also revealed a $31.3 million goodwill impairment related to its recent acquisition of Fabric Genomics. Following these disclosures, a class action lawsuit was filed alleging that GeneDx misled investors about the importance of Fabric Genomics, reimbursement rates, and profit margins. Investors have 60 days to join the lawsuit or seek lead plaintiff status.